Detalhe da pesquisa
1.
A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison.
Biometrics
; 80(1)2024 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38364811
2.
Current issues in dose-finding designs: A response to the US Food and Drug Adminstrations's Oncology Center of Excellence Project Optimus.
Clin Trials
; : 17407745241234652, 2024 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38570906
3.
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial.
Lancet Oncol
; 24(12): 1387-1398, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38039992
4.
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
N Engl J Med
; 382(6): 545-553, 2020 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32023374
5.
Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicity.
Biometrics
; 79(3): 2458-2473, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35974457
6.
Risk-benefit trade-offs and precision utilities in phase I-II clinical trials.
Clin Trials
; : 17407745231214750, 2023 Dec 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38111231
7.
BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials.
Clin Trials
; 20(5): 486-496, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37313712
8.
A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint.
Pharm Stat
; 22(1): 34-44, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35851545
9.
Generalized phase I-II designs to increase long term therapeutic success rate.
Pharm Stat
; 22(4): 692-706, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37038957
10.
Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers.
Biometrics
; 78(1): 60-71, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33438761
11.
Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis.
Cancer
; 127(8): 1228-1237, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33306202
12.
Matched Pairs Comparison of an Enhanced Recovery Pathway Versus Conventional Management on Opioid Exposure and Pain Control in Patients Undergoing Lung Surgery.
Ann Surg
; 274(6): 1099-1106, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32229762
13.
Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups.
Stat Med
; 40(24): 5199-5217, 2021 10 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34636054
14.
An adaptive trial design to optimize dose-schedule regimes with delayed outcomes.
Biometrics
; 76(1): 304-315, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31273750
15.
A phase I-II design based on periodic and continuous monitoring of disease status and the times to toxicity and death.
Stat Med
; 39(15): 2035-2050, 2020 07 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32255206
16.
Comparing Bayesian early stopping boundaries for phase II clinical trials.
Pharm Stat
; 19(6): 928-939, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32720462
17.
A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III.
Biometrics
; 75(2): 371-381, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30367457
18.
Bayesian variable selection based on clinical relevance weights in small sample studies-Application to colon cancer.
Stat Med
; 38(12): 2228-2247, 2019 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30672015
19.
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Biol Blood Marrow Transplant
; 24(8): 1602-1609, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29501779
20.
A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups.
Biometrics
; 74(3): 1095-1103, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29359314